Palliative Resection of the Primary Tumor

Introduction

Despite widespread screening for cancer detection, approximately one-fifth of individuals are identified with metastases. Chemotherapy and other palliative modalities are currently being advocated for these people as part of palliative treatment to manage pain and improve their quality of life. Furthermore, only about 15 % of individuals require surgical or other primary treatments. As a result, the relevance of surgical resection of initial tumors is debatable.

Although numerous studies have suggested that surgical resection of a primary tumor improves patient survival, the influence of palliative resection of initial tumors on overall survival is unknown.

What Is Palliative Resection?

Palliative surgery is a resection with microscopic or large residual tumors left in place after the operation and a resection performed for persistent or recurrent illness following therapy failure. Currently, palliative resection or surgery refers to all surgical procedures performed to enhance the quality of life by alleviating symptoms caused by a terminal disease. This new rigorous definition is consistent with the recognized concepts of nonsurgical palliative care. Furthermore, it distinguishes itself from non-curative surgery, which refers to surgeries with a curative purpose in asymptomatic patients that result in a non-oncological outcome. Nevertheless, palliative surgery is prevalent in surgical oncology treatment, accounting for 10 to 20 percent of all procedures.

What Diseases Are Treated With Palliative Resection of the Primary Tumor?

Palliative removal of the original lesion is indicated for functional tumors generating intractable secretory symptoms, such as small intestine neuroendocrine tumors with impending intestinal obstruction or recurrent bleeding. Primary tumor resection may provide a survival benefit in incurable small intestine neuroendocrine tumors (SI NETs), and palliative resection should be considered after a comprehensive assessment of the comorbidities and functional state of the patient.

What Is the Role of Palliative Resection in Gastric Cancer?

Gastric cancer is the world's third most significant cause of cancer-related death. While palliative chemotherapy is the gold standard for patients with recurrent or primary metastatic gastric cancer, surgical resection metastasectomy and palliative gastrectomy with or without metastasectomy is frequently performed for potentially resectable lesions. Furthermore, palliative gastrectomy is often recommended in cases of potentially life-threatening blockage, perforation, or bleeding. However, the usefulness of palliative surgical resection in current or primary metastatic gastric cancer (RPMGC) treatment is still debatable in general. Nevertheless, many studies have suggested that adding surgical resection to treatment may improve survival in current or primary metastatic gastric cancer.

What Are the Indications of Palliative Resection in Gastric Cancer?

The indications of palliative resection in gastric cancer are as follows:

• Metastatic primary illness.

• Severe bleeding.

• Perforation and obstruction.

• Non-surgical intervention is ineffective.

What Is the Role of Palliative Resection in Pancreatic Cancer?

Despite all advances in surgical and other conservative therapy, pancreatic cancer continues to be linked with a poor overall prognosis and is a leading cause of cancer mortality. Radical surgical resection has been proven to be the most incredible option for long-term survival. However, in most instances, the disease has progressed to an incurable stage at diagnosis, owing to its silent clinical course in its early stages. Therefore, palliative surgery is used in patients with locally advanced pancreatic cancer discovered unresectable during open surgical exploration and consists of combined biliary and duodenal bypass surgeries.

What Are the Indications of Palliative Resection in Pancreatic Cancer?

• Palliative surgery is reserved for patients whose nonsurgical therapy has failed or has resulted in severe problems, such as penetration, bleeding, or stent blockage.

• Patients with pancreatic cancer found unresectable after the staging laparotomy are mostly treated with palliative surgical therapy.

How Is Palliative Resection Assessed?

The complication rate for palliative surgery is substantial and not restricted to major surgeries. A validated instrument monitors quality of life (QOL) outcomes for palliative surgical treatments.

The European Organization for Research and Treatment of Cancer (EORTC) utilizes the QLQ-C30 Core Module and Functional Assessment of Cancer Therapy (FACT) for surgical patients. The Palliative Surgery Outcome Score (PSOS) is a prospective assessment of the impact of palliative surgery that includes the absence of a postoperative complication that necessitates hospitalization as part of the quality of life (QOL) outcomes measurement following palliative surgery.

What Is Extended Excision of the Primary Tumor?

Extended excision of the original tumor can prevent loco-regional consequences. Furthermore, because primary tumors and residual regional lymph nodes can be sources of immunosuppressive cytokines such as transforming growth factor beta, granulocyte-macrophage colony-stimulating factor, and prostaglandin E2, extended primary tumor resection can dampen the immunosuppressive microenvironment.

These surviving lymph nodes contain immune and stromal cells expressing diverse markers to extend cancer cell survival. In addition, current research suggests that CD8+ T cells destroy myeloid cells in lymph nodes to prevent tumor cell colonization. As a result, surviving lymph nodes play a critical role in tumor growth.

What Is the Advantage of Extended Excision Over Palliative Resection?

Over the previous three decades, specialized centers have increased the overall resection rate in pancreatic cancer patients to 40 to 50 % while lowering the perioperative mortality rate to one to two percent. Nonetheless, only a portion of these treatments achieves the requirements for total tumor removal, keeping the overall prognosis dismal. Despite significant breakthroughs in imaging technology, surgical exploration remains the only technique to determine resectability in the case of a non-conclusive diagnosis. Furthermore, the resectability of pancreatic tumors dramatically depends on each surgeon's experience and the hospital's case volume.

When Should Palliative Resection Be Performed for a Primary Tumor?

It is crucial to determine the need for palliative resection correctly. The doctors should not use it for R1 resection, which means macroscopically radical excision but is microscopically non-radical following pathologic evaluation. Palliative resection should only be used for R2 resections, which are intended to have macroscopically positive margins. It primarily refers to cases in which the tumor is discovered to be unresectable after a point of no return or resection for preoperative tumor hemorrhage that has not responded to embolization or other conservative approaches.

Conclusion

Palliative primary tumor resection is employed as an additional therapeutic option. Palliative resection, however still a contentious issue. In cases of doubtful resection, a palliative resection can provide adequate tumor resection, especially in patients with advanced pancreatic cancer. Even though pancreatic cancer frequently emerges during exploratory laparotomy at a stage where R0 resection is impossible, an aggressive surgical approach to the tumor may be an appropriate alternative to enhance the patient's prognosis. On the other hand, it is universally agreed that doctors should not undertake resections in individuals who are unquestionably unresectable during the preoperative diagnostic workup.